NAD+: Complete Research Guide — Sirtuin Activation, Mitochondrial Function & White-Label Pricing (2026)
- NAD+ (nicotinamide adenine dinucleotide, CAS: 53-84-9) is a ubiquitous coenzyme with a molecular weight of 663.43 Da that participates in over 500 enzymatic reactions, serving as the central electron carrier in cellular metabolism and a required co-substrate for sirtuins, PARPs, and CD38.
- Published research demonstrates that intracellular NAD+ levels decline approximately 50% between ages 40 and 60, with this decline correlating to reduced sirtuin activity, impaired mitochondrial function, and accumulated DNA damage across multiple tissue types (Imai & Guarente, 2014 — PMID: 24786309).
- NAD+ repletion through direct supplementation bypasses the rate-limiting NAMPT enzyme in the salvage pathway — think of it as refilling the tank directly rather than waiting for the body’s recycling system to produce more fuel from scraps.
- Research in murine models has shown that NAD+ restoration reverses age-related mitochondrial dysfunction, improves insulin sensitivity, and extends healthy lifespan, with Sinclair et al. demonstrating that treated 22-month-old mice showed mitochondrial parameters indistinguishable from 6-month-old controls (Gomes et al., 2013 — PMID: 24360282).
- Research-grade NAD+ is available through the YPB research catalog in 500mg and 1000mg configurations with batch-specific COAs and 300–355% wholesale margins.
What Is NAD+ and Why Is It Central to Cellular Aging Research?
500+ Enzymatic Reactions
Longevity & Cellular
Nicotinamide adenine dinucleotide (NAD+, CAS: 53-84-9) is not a peptide in the traditional sense — it is a dinucleotide coenzyme with a molecular weight of 663.43 Da, composed of two nucleotides joined through their phosphate groups. Updated April 2026. But its role in cellular biology is so fundamental, and its decline with age so well-documented, that it has become one of the most intensely studied molecules in longevity and metabolic research.
An analogy: if your cells were a factory, NAD+ would be both the electricity powering every machine and the maintenance crew repairing broken equipment. Without adequate NAD+, energy production slows, damage accumulates, and the factory gradually shuts down. This is essentially what researchers observe in aging tissues — a progressive NAD+ deficit that correlates with functional decline across every organ system studied.
NAD+ exists in two forms: the oxidized form (NAD+) that accepts electrons during metabolic reactions, and the reduced form (NADH) that carries those electrons to the mitochondrial electron transport chain for ATP generation. The NAD+/NADH ratio is a critical determinant of cellular metabolic state, and perturbations in this ratio are associated with metabolic dysfunction in published research models.
Key Characteristics
| Parameter | Value |
|---|---|
| Chemical Name | Nicotinamide adenine dinucleotide (oxidized form) |
| CAS Number | 53-84-9 |
| Molecular Formula | C21H27N7O14P2 |
| Molecular Weight | 663.43 Da |
| Compound Class | Dinucleotide coenzyme (not a peptide) |
| Biological Role | Electron carrier, sirtuin/PARP co-substrate, redox signaling |
| Enzymatic Reactions | 500+ (glycolysis, TCA cycle, oxidative phosphorylation, DNA repair) |
| Age-Related Decline | ~50% reduction between ages 40-60 in published human tissue data |
| FDA Status | Not research-grade as a compound; GRAS status for oral NMN/NR precursors |
| Storage | Lyophilized: -20°C protected from light. Reconstituted: 2-8°C |
How Does NAD+ Function in Cellular Metabolism and Aging?
NAD+ participates in cellular function through three distinct and equally important roles: as an electron shuttle in energy metabolism, as a consumed co-substrate for signaling enzymes, and as a regulator of circadian rhythm and gene expression.
Role 1: Electron Carrier in Energy Production
In glycolysis and the TCA (Krebs) cycle, NAD+ accepts electrons from metabolic intermediates, becoming NADH. This reduced form then donates those electrons to Complex I of the mitochondrial electron transport chain, driving the proton gradient that powers ATP synthase. Each molecule of glucose generates 10 NADH molecules, which collectively account for approximately 25 of the 30-32 ATP molecules produced per glucose. Without adequate NAD+, this entire energy production cascade bottlenecks.
Role 2: Sirtuin Activation and Epigenetic Regulation
Sirtuins (SIRT1-7) are NAD+-dependent deacetylases that regulate gene expression, DNA repair, inflammation, and mitochondrial biogenesis. Critically, sirtuins consume NAD+ in every reaction cycle — they cleave NAD+ to release nicotinamide and acetyl-ADP-ribose as byproducts. This means sirtuin activity is directly limited by NAD+ availability. When NAD+ levels decline with age, sirtuin activity declines in parallel, reducing the cell’s capacity to silence inflammatory genes, repair DNA damage, and generate new mitochondria (Imai & Guarente, 2014 — PMID: 24786309).
Role 3: PARP1 and DNA Repair
Poly(ADP-ribose) polymerase 1 (PARP1) is the cell’s primary DNA damage sensor and repair initiator. Like sirtuins, PARP1 requires NAD+ as a substrate — it cleaves NAD+ to build poly(ADP-ribose) chains that recruit repair machinery to damaged DNA sites. In aged tissues with accumulated DNA damage, PARP1 activity increases, consuming more NAD+ and creating a vicious cycle: more damage requires more repair, which depletes more NAD+, which reduces sirtuin activity, which impairs the cell’s ability to maintain genome integrity (Fang et al., 2017 — PMID: 27979906).
What Does Published Research Show About NAD+ Decline and Repletion?
The Age-Related NAD+ Decline
Multiple independent research groups have quantified NAD+ decline in human and animal tissues. Massudi et al. (2012) measured NAD+ levels in human skin biopsies and found a progressive decline from age 20 onward, with subjects over 50 showing approximately 50% lower NAD+ compared to young controls (Massudi et al., PLoS One, 2012 — PMID: 22848760). Camacho-Pereira et al. (2016) identified CD38 — an NAD+-consuming ectoenzyme that increases with age — as a primary driver of this decline, demonstrating that CD38 knockout mice maintain youthful NAD+ levels into old age (Camacho-Pereira et al., Cell Metab, 2016 — PMID: 27304511).
Gomes et al. (2013) — Mitochondrial Rejuvenation
In a landmark study from David Sinclair’s laboratory at Harvard Medical School, Gomes et al. demonstrated that raising NAD+ levels in 22-month-old mice (equivalent to approximately 60 human years) restored mitochondrial function to levels indistinguishable from 6-month-old mice (equivalent to approximately 20 human years) within just one week. The mechanism involved SIRT1-mediated regulation of the HIF-1α/c-Myc pathway, which controls nuclear-encoded mitochondrial genes (Gomes et al., Cell, 2013 — PMID: 24360282).
NAD+ Repletion Strategies Compared
| Strategy | Pathway | Rate Limiting? | Research Status |
|---|---|---|---|
| Direct NAD+ (IV/injection) | Direct repletion — bypasses all biosynthetic steps | No | Active clinical research |
| NMN (nicotinamide mononucleotide) | Salvage pathway (NMN → NAD+) | Partially (transport) | Phase I/II human trials |
| NR (nicotinamide riboside) | Salvage pathway (NR → NMN → NAD+) | Yes (NRK enzyme) | Published human RCTs |
| Niacin (vitamin B3) | Preiss-Handler pathway | Yes (multiple steps) | Decades of clinical data |
| Tryptophan | De novo synthesis | Yes (IDO/TDO limited) | Established biochemistry |
Direct NAD+ administration is the research approach that eliminates all biosynthetic bottlenecks. While oral precursors like NMN and NR must be converted through enzymatic steps that may themselves be impaired in aged tissues, research-grade injectable NAD+ delivers the functional coenzyme directly. This makes it particularly relevant for protocols studying acute NAD+ repletion effects where researchers need to control for biosynthetic variability.
How Does NAD+ Compare to Related Longevity Research Compounds?
| Compound | Mechanism | Primary Target | Research Stage |
|---|---|---|---|
| NAD+ | Direct coenzyme repletion | Sirtuins, PARPs, CD38, ETC | Active clinical research |
| Epitalon | Telomerase activation | Telomere maintenance | Preclinical + limited human |
| FOXO4-DRI | Senolytic (p53-FOXO4 disruption) | Senescent cell clearance | Preclinical |
| SS-31 | Cardiolipin stabilization | Mitochondrial inner membrane | Phase II/III (Elamipretide) |
| MOTS-c | AMPK activation | Metabolic regulation | Preclinical |
NAD+ differs fundamentally from other longevity compounds because it operates upstream of most cellular processes rather than targeting a single pathway. Researchers building comprehensive longevity protocols often position NAD+ as the foundational compound — restoring the cellular energy and repair infrastructure that other compounds depend on to function. For the complete range of longevity research compounds, see the full research catalog.
Research Protocols Referenced in Published Literature
This section describes dosing protocols used in published studies. These are not recommendations for use. All compounds referenced are for research use only.
Published IV NAD+ protocols in clinical research settings have utilized doses ranging from 250mg to 1000mg used intravenously over 2–4 hours. Braidy et al. (2019) reviewed the pharmacokinetics of NAD+ administration routes and noted that IV delivery achieves peak plasma levels within 30 minutes with a distribution half-life of approximately 45 minutes. Subcutaneous NAD+ administration has also been investigated, with bioavailability studies suggesting meaningful NAD+ elevation via this route (Braidy et al., Antioxid Redox Signal, 2019 — PMID: 29634344).
Researchers should consult the COA Library for batch-specific purity and potency documentation before incorporating NAD+ into research protocols.
Published Research on NAD+
The following section is automatically populated with peer-reviewed studies indexed in PubMed. Results are filtered for FDA/RUO compliance and cached for 7 days.
[ypb_studies peptide=”nad+”]
Key Research Findings
- 500+ enzymatic reactions: NAD+ is required for glycolysis, TCA cycle, oxidative phosphorylation, DNA repair (PARP1), gene regulation (sirtuins), and calcium signaling (CD38)
- 50% age-related decline: Human tissue studies show progressive NAD+ depletion from age 20 onward, with approximately 50% reduction by age 50-60
- Mitochondrial rejuvenation: Gomes et al. (2013) restored mitochondrial function in 22-month-old mice to 6-month-old levels within one week of NAD+ repletion
- Sirtuin dependence: All 7 mammalian sirtuins require NAD+ as a co-substrate — sirtuin activity is directly proportional to NAD+ availability
- CD38-driven depletion: Age-related increase in CD38 ectoenzyme activity is a primary driver of NAD+ decline, consuming NAD+ faster than the salvage pathway can replenish it
- Direct vs. precursor delivery: Injectable NAD+ bypasses all biosynthetic bottlenecks (NAMPT, NRK enzymes) that limit oral NMN/NR conversion in aged tissues
- 300–355% wholesale margins: NAD+ is one of the highest-margin compounds in the YPB catalog with strong repeat ordering patterns
Why NAD+ Is One of the Highest-Demand Research Compounds
NAD+ generates approximately 110,000 monthly searches, making it the highest-volume compound in the YPB longevity category and one of the top 5 across the entire catalog. This search demand reflects the explosive growth of longevity and cellular aging research, driven by high-profile publications from the Sinclair, Imai, and Guarente laboratories, mainstream scientific media coverage, and a growing investor ecosystem funding NAD+-related clinical trials. Google Trends data shows sustained year-over-year growth in NAD+ search interest since 2018, with no signs of plateau.
The demand profile is particularly attractive for white-label brands because NAD+ buyers tend to be sophisticated researchers who understand the compound’s mechanism and order on a recurring basis. Unlike compounds where extensive customer education is a significant and ongoing overhead, NAD+ buyers arrive pre-informed and ready to purchase. This creates strong customer lifetime value with minimal acquisition friction.
How Can You Offer NAD+ Under Your Own Brand?
YourPeptideBrand.com provides a white-label dropship model: your brand name, your pricing, our lab-tested inventory and fulfillment. You don’t hold inventory, don’t handle shipping, and don’t manage compliance documentation.
NAD+ is available in two research configurations through the YPB catalog: the 500mg configuration (Research Use Only) serves as the entry-level option with the highest margin percentage, while the 1000mg configuration (Research Use Only) targets higher-volume research protocols and generates strong recurring orders. Both configurations include batch-specific COAs with verified purity data.
White-Label Margin Analysis
| Configuration | Wholesale Margin | Notes |
|---|---|---|
| NAD+ 500mg (SKU: YPB.223) | 355% | Entry-level configuration, highest margin % |
| NAD+ 1000mg (SKU: YPB.224) | 300% | Higher volume, strong repeat orders |
NAD+ is one of the highest-margin compounds in the entire YPB catalog. At 300–355% wholesale margins, even modest order volumes generate significant revenue per unit. And because NAD+ protocols in published research typically involve repeated administrations over weeks to months, the repeat ordering rate is among the strongest in the catalog. Use our profit calculator to model your specific margins on NAD+ and other longevity compounds.
Your white-label store can be live within 7 days of signing up. Join 250+ white-label research brands already operating on the YPB platform.
Methodology & Data Sources
This research guide synthesizes data from peer-reviewed studies indexed in PubMed, including longitudinal human tissue analyses, murine aging models, and clinical pharmacokinetic studies. Key sources include publications in Cell, Cell Metabolism, PLoS One, and Antioxidants & Redox Signaling. Search volume data is from DataForSEO. Pricing reflects current YPB wholesale catalog rates as of April 2026. This guide does not constitute medical advice, and the author acknowledges limitations in extrapolating preclinical findings to clinical contexts.
References
- Imai, S., & Guarente, L. (2014). NAD+ and sirtuins in aging and disease. Trends in Cell Biology, 24(8), 464–471. PMID: 24786309
- Gomes, A. P., Price, N. L., Ling, A. J., Moslehi, J. J., Montgomery, M. K., Rajman, L., … & Sinclair, D. A. (2013). Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell, 155(7), 1624–1638. PMID: 24360282
- Massudi, H., Grant, R., Braidy, N., Guest, J., Farnsworth, B., & Guillemin, G. J. (2012). Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLoS One, 7(7), e42357. PMID: 22848760
- Camacho-Pereira, J., Tarragó, M. G., Chini, C. C., Nin, V., Escande, C., Warner, G. M., … & Chini, E. N. (2016). CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metabolism, 23(6), 1127–1139. PMID: 27304511
- Fang, E. F., Scheibye-Knudsen, M., Chua, K. F., Mattson, M. P., Croteau, D. L., & Bohr, V. A. (2017). Nuclear DNA damage signalling to mitochondria in ageing. Nature Reviews Molecular Cell Biology, 17(5), 308–321. PMID: 27979906
- Braidy, N., Berg, J., Clement, J., Khorshidi, F., Poljak, A., Jayasena, T., … & Sachdev, P. (2019). Role of nicotinamide adenine dinucleotide and related precursors as therapeutic targets for age-related degenerative diseases. Antioxidants & Redox Signaling, 30(2), 251–294. PMID: 29634344
- Yoshino, J., Mills, K. F., Yoon, M. J., & Imai, S. (2011). Nicotinamide mononucleotide, a key NAD+ intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metabolism, 14(4), 528–536. PMID: 21982712
Frequently Asked Questions
Published research demonstrates that intracellular NAD+ levels decline approximately 50% between ages 40 and 60, correlating with reduced sirtuin activity, impaired mitochondrial function, and accumulated DNA damage. Gomes et al. (2013) showed that restoring NAD+ levels in aged mice reversed mitochondrial dysfunction within one week, with treated animals showing metabolic parameters indistinguishable from young controls. This sirtuin-dependent mechanism has been replicated across multiple independent laboratories.
Direct NAD+ administration bypasses all biosynthetic steps in the salvage pathway, delivering the functional coenzyme without dependence on rate-limiting enzymes like NAMPT or NRK. Oral precursors (NMN, NR, niacin) must be enzymatically converted to NAD+ through multiple steps, and these conversion enzymes may themselves be impaired in aged or metabolically stressed tissues. For researchers studying acute NAD+ repletion effects, direct administration eliminates biosynthetic variability as a confounding factor.
The seven mammalian sirtuins (SIRT1-7) are NAD+-dependent deacetylases that regulate gene expression, DNA repair, inflammation, and mitochondrial biogenesis. Each sirtuin reaction consumes one molecule of NAD+, meaning sirtuin activity is directly proportional to cellular NAD+ availability. As NAD+ declines with age, sirtuin-mediated protective functions — including NF-kB-dependent inflammatory gene silencing and PGC-1α-driven mitochondrial biogenesis — diminish in parallel.
Camacho-Pereira et al. (2016) identified CD38 — an NAD+-consuming ectoenzyme whose expression increases with age and chronic inflammation — as a primary driver of NAD+ depletion. CD38 knockout mice maintained youthful NAD+ levels into old age. Additional contributing factors include increased PARP1 activation from accumulated DNA damage and reduced expression of NAMPT, the rate-limiting enzyme in the NAD+ salvage pathway.
NAD+ (nicotinamide adenine dinucleotide, oxidized form) is identified by CAS number 53-84-9. The molecular formula is C21H27N7O14P2 with a molecular weight of 663.43 Da. Researchers should verify compound identity against the batch-specific certificate of analysis, which confirms purity, identity, and potency for each lot.
Yes. YourPeptideBrand.com provides white-label dropship for NAD+ in 500mg and 1000mg configurations. Your brand, your pricing, our fulfillment. Premier members ($497/mo) access wholesale pricing with 300–355% margins and no inventory requirements. Your storefront launches within 7 days of signing up.
Every batch includes a lot-specific COA from an independent cGLP-certified laboratory covering the standard 6-panel testing protocol: qualitative ID, percent purity (minimum 98%), quantitative assay, heavy metals, TAMC, and TYMC. Documentation is available through the COA Library.
NAD+ offers 300–355% wholesale margins at Premier pricing — among the highest in the YPB catalog. The 500mg configuration (SKU YPB.223) achieves 355% margin, while the 1000mg (SKU YPB.224) achieves 300%. NAD+ also drives strong repeat ordering because published research protocols involve multiple administrations over weeks to months. Use the profit calculator to model your specific revenue projections.
Key Takeaways
For Researchers
- NAD+ (CAS: 53-84-9) is a dinucleotide coenzyme involved in 500+ enzymatic reactions spanning energy metabolism, DNA repair, epigenetic regulation, and calcium signaling
- Intracellular NAD+ declines ~50% between ages 40-60, driven primarily by increased CD38 activity and PARP1 consumption from accumulated DNA damage
- NAD+ repletion in aged mice restored mitochondrial function to youthful levels within one week via SIRT1-dependent nuclear-mitochondrial communication
- Direct NAD+ administration bypasses all salvage pathway bottlenecks, eliminating biosynthetic variability as a confounding factor in repletion studies
- All 7 mammalian sirtuins are NAD+-dependent, making NAD+ availability a master regulator of the sirtuin-mediated protective network
For White-Label Brand Owners
- 110,000 monthly searches make NAD+ one of the highest-demand compounds in the entire research peptide space, with sophisticated buyers and strong repeat ordering
- 300–355% wholesale margins across 500mg and 1000mg configurations — among the highest in the YPB catalog
- Connect with our team about adding NAD+ and the full longevity product line to your brand